National trends in utilisation of glucose lowering medicines by older people with diabetes in long-term care facilities
Authors' conclusion
The increasing use of insulin and ongoing use of sulfonylureas suggests a need to implement evidence-based strategies to optimise diabetes care in LTCFs.
Study context
- Population
- Individuals ≥65 years with diabetes in Australian long-term care facilities (LTCFs), 2009–2019
- Participants
- 140,322 individuals
- Exposure
- Glucose lowering medicine (GLM) use in 2019 vs 2009
- Outcome
- Annual age-sex standardised prevalence of glucose lowering medicine (GLM) use
- Follow-up
- 2009-2019
Methodological detailsnational, age-sex standardised prevalence, multivariable Poisson or negative binomial regression
- National
- Age-sex standardised prevalence
- Multivariable Poisson or negative binomial regression
Main finding
As reported in the abstract
Prevalence of GLM use · 2009 to 2019
- aRR (95% CI 1.00-1.00); prevalence remained steady
- 1.00
Observational data: associations, not effects.
Further findings
Metformin use (% of residents)
- Metformin use increased
- from 36.0% (95 %CI 35.3-36.7) to 43.5% (95 %CI 42.9-44.1)
- aRR
- 1.01, 95 %CI 1.01-1.01
Insulin use (% of residents)
- Insulin use increased
- from 21.5% (95 %CI 21.0-22.0) to 27.0% (95 %CI 26.5-27.5)
- aRR
- 1.02, 95 %CI 1.02-1.02
DPP-4i use (% of residents)
- DPP-4i use increased
- from 1.0% (95 %CI 0.9-1.1) to 21.1% (95 %CI 20.7-21.5)
- aRR
- 1.24, 95 %CI 1.24-1.25
SU use (% of residents)
- SU use decreased
- from 34.4% (95 %CI 33.8-35.1) to 19.3% (95 %CI 18.9-19.7)
- aRR
- 0.93, 95 %CI 0.93-0.94
Defined daily doses (DDDs)/1000 resident-days
- Similar trends were observed in DDDs/1000 resident days
Original publication
National trends in utilisation of glucose lowering medicines by older people with diabetes in long-term care facilities. Diabetes Res Clin Pract. Published 7 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →